[ad_1]
Anvisa does not report whether the study participant was prescribed a dose of vaccine or a placebo, the journal said. The health service has not yet ruled on this issue.
However, according to the person involved in this case, the participant who died during the COVID-19 vaccine trials did not receive a dose of the company-developed vaccine.
The aforementioned person requested that his identity be withheld, since this information is not public.
Brazil’s health service Anvisa said it was informed on Monday of the death of a volunteer who participated in the study and received a partial report from the international committee assessing the study’s safety.
According to Anvisa in its report, the committee in its conclusions suggests that the vaccine trials be continued.
AstraZeneca, the co-developer of the coronavirus vaccine with the University of Oxford, says it cannot comment on individual cases due to confidentiality provisions and clinical trial rules.
The University of Oxford has no suspicions about the safety of vaccine trials after extensive independent review. Brazilian regulators recommend continuing the investigation, said the report Stephen Rouse, the university’s communications director.
Shares of AstraZeneca fell as much as 3.3 percent on Wednesday afternoon after learning of the death of a participant, but recent trading has reduced those losses.
Filling
[ad_2]
